Open-label crossover study for the efficasy of Escitalopram and Mecobalamin for patients with tinnitus.

Open-label crossover study for the efficasy of Escitalopram and Mecobalamin for patients with tinnitus. - The efficasy of Escitalopram for patients with tinnitus.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000013421

Enrollment

Registered

2014-04-01

Start date

2014-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

tinnitus

Interventions

Take Escitalopram Take Mecobalamin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. with tinnitus 2.no changein spite of therapy for one month. 3.with depressive state 4. with informed consent

Exclusion criteria

Exclusion criteria: 1.allergy for Escitalopram 2.arrhythmia and QT prolongation 3.heart failure 4.hepatic disorder 5.mental disorder 6.epilepsy 7.lactating 8.others

Design outcomes

Primary

Measure	Time frame
Change of Tinnitus Handicap Inventory	—

Countries

Japan

Contacts

Public ContactYuji Nakamaru

Hokkaido University Hospital Department of Otolaryngology

nmaru@med.hokudai.ac.jp011-716-1161

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026